Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Fig. 2

PFS between alectinib and ceritinb in (a) subgroup of patients of crizotinib treatment failure due to intolerance (17 patients received alectinib and 8 patients received ceritinib in which 4 and 6 events were observed, respectively) and in (b) subgroup of patients of crizotinib treatment failure due to resistance (26 patients received alectinib and 14 patients received ceritinib in which 16 and 11 events were observed, respectively)

Back to article page